Vorhofflimmern: Orale Antikoagulation bei Kardioversion

Arzt hält ein Elektroden für eine Kardioversion in Händen.

© sudok1 / Fotolia

Die elektrische Kardioversion erfolgt unter kontinuierlicher EKG-Überwachung.


  1. Kirchhof P et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS: The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC Endorsed by the European Stroke Organisation (ESO). Europace 2016.
  2. Lip GY et al. Overtreatment and undertreatment with anticoagulation in relation to cardioversion of atrial fibrillation (the RHYTHM-AF study). Am J Cardiol 2014; 113: 480–484.
  3. Palomaki A et al. Strokes after cardioversion of atrial fibrillation -The FibStroke study. Int J Cardiol 2016; 203: 269–273.
  4. Klein AL et al. Role of transesophageal echocardiography-guided cardioversion of patients with atrial fibrillation. J Am Coll Cardiol 2001; 37: 691–704.
  5. Klein HH et al. Cardioversion in Non-Valvular Atrial Fibrillation. Dtsch Arztebl Int 2015; 112: 856–862.
  6. Plitt A et al. Cardioversion of Atrial Fibrillation in ENGAGE AF-TIMI 48. Clin Cardiol 2016; 39: 345–346.
  7. Nagarakanti R et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation 2011; 123: 131–136.
  8. Flaker G et al. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). J Am Coll Cardiol 2014; 63: 1082–1087.
  9. Heidbuchel H et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015; 17: 1467–1507.
  10. Goette A et al. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial. Lancet 2016.